Restoration of NBD1 thermal stability is necessary and sufficient to correct ∆F508 CFTR folding and assembly.

Cystic fibrosis transmembrane conductance regulator (CFTR) (ABCC7), unique among ABC exporters as an ion channel, regulates ion and fluid transport in epithelial tissues. Loss of function due to mutations in the cftr gene causes cystic fibrosis. The most common cystic-fibrosis-causing mutation, the deletion of F508 (ΔF508) from the first nucleotide binding domain (NBD1) of CFTR, results in misfolding of the protein and clearance by cellular quality control systems. The ΔF508 mutation has two major impacts on CFTR: reduced thermal stability of NBD1 and disruption of its interface with membrane-spanning domains (MSDs). It is unknown if these two defects are independent and need to be targeted separately. To address this question, we varied the extent of stabilization of NBD1 using different second-site mutations and NBD1 binding small molecules with or without NBD1/MSD interface mutation. Combinations of different NBD1 changes had additive corrective effects on ∆F508 maturation that correlated with their ability to increase NBD1 thermostability. These effects were much larger than those caused by interface modification alone and accounted for most of the correction achieved by modifying both the domain and the interface. Thus, NBD1 stabilization plays a dominant role in overcoming the ΔF508 defect. Furthermore, the dual target approach resulted in a locked-open ion channel that was constitutively active in the absence of the normally obligatory dependence on phosphorylation by protein kinase A. Thus, simultaneous targeting of both the domain and the interface, as well as being non-essential for correction of biogenesis, may disrupt normal regulation of channel function.

[1]  S. Gullans,et al.  Mammalian Osmolytes and S-Nitrosoglutathione Promote ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein Maturation and Function* , 2003, Journal of Biological Chemistry.

[2]  H. Senderowitz,et al.  The Cystic Fibrosis-causing Mutation ΔF508 Affects Multiple Steps in Cystic Fibrosis Transmembrane Conductance Regulator Biogenesis* , 2010, The Journal of Biological Chemistry.

[3]  K. Du,et al.  Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and Function , 2012, Cell.

[4]  J. Riordan,et al.  Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  Jordi Villà-Freixa,et al.  New Model of Cystic Fibrosis Transmembrane Conductance Regulator Proposes Active Channel-like Conformation , 2012, J. Chem. Inf. Model..

[6]  Zhengrong Yang,et al.  Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis , 2010, Protein science : a publication of the Protein Society.

[7]  J. Riordan,et al.  F508del CFTR with two altered RXR motifs escapes from ER quality control but its channel activity is thermally sensitive. , 2006, Biochimica et biophysica acta.

[8]  J. Riordan,et al.  CFTR function and prospects for therapy. , 2008, Annual review of biochemistry.

[9]  H. A. Berger,et al.  Identification of revertants for the cystic fibrosis ΔF508 mutation using STE6-CFTR chimeras in yeast , 1993, Cell.

[10]  Zhengrong Yang,et al.  Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide‐binding domain 1 , 2010, Protein science : a publication of the Protein Society.

[11]  Adrian W. R. Serohijos,et al.  Phenylalanine-508 mediates a cytoplasmic–membrane domain contact in the CFTR 3D structure crucial to assembly and channel function , 2008, Proceedings of the National Academy of Sciences.

[12]  Soo-Jung Kim,et al.  Mechanisms of CFTR Folding at the Endoplasmic Reticulum , 2012, Front. Pharmacol..

[13]  J. Riordan,et al.  Protein kinase A (PKA) still activates CFTR chloride channel after mutagenesis of all 10 PKA consensus phosphorylation sites. , 1993, The Journal of biological chemistry.

[14]  A. Verkman,et al.  Cystic fibrosis transmembrane regulator correctors and potentiators. , 2013, Cold Spring Harbor perspectives in medicine.

[15]  G. Cutting,et al.  Localization studies of rare missense mutations in cystic fibrosis transmembrane conductance regulator (CFTR) facilitate interpretation of genotype‐phenotype relationships , 2008, Human mutation.

[16]  D. Clarke,et al.  The V510D Suppressor Mutation Stabilizes ΔF508-CFTR at the Cell Surface† , 2010, Biochemistry.

[17]  Xuehong Liu,et al.  Thermal instability of ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) channel function: protection by single suppressor mutations and inhibiting channel activity. , 2012, Biochemistry.

[18]  James Rader,et al.  Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[19]  Isabelle Callebaut,et al.  Molecular models of the open and closed states of the whole human CFTR protein , 2009, Cellular and Molecular Life Sciences.

[20]  R. Kopito,et al.  Biosynthesis and degradation of CFTR. , 1999, Physiological reviews.

[21]  Matthew P. Anderson,et al.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive , 1992, Nature.

[22]  Adrian W. R. Serohijos,et al.  Computational studies reveal phosphorylation-dependent changes in the unstructured R domain of CFTR. , 2008, Journal of molecular biology.

[23]  Philip J. Thomas,et al.  Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved Sequences , 2012, Cell.

[24]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[25]  Nikolay V. Dokholyan,et al.  Multiple Membrane-Cytoplasmic Domain Contacts in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mediate Regulation of Channel Gating* , 2008, Journal of Biological Chemistry.

[26]  J. M. Sauder,et al.  Structure of nucleotide‐binding domain 1 of the cystic fibrosis transmembrane conductance regulator , 2004, The EMBO journal.

[27]  J. Wine,et al.  Glycerol Reverses the Misfolding Phenotype of the Most Common Cystic Fibrosis Mutation (*) , 1996, The Journal of Biological Chemistry.

[28]  J. M. Sauder,et al.  Impact of the ΔF508 Mutation in First Nucleotide-binding Domain of Human Cystic Fibrosis Transmembrane Conductance Regulator on Domain Folding and Structure* , 2005, Journal of Biological Chemistry.

[29]  J. Riordan,et al.  Cytoplasmic Loop Three of Cystic Fibrosis Transmembrane Conductance Regulator Contributes to Regulation of Chloride Channel Activity* , 1996, The Journal of Biological Chemistry.

[30]  J. Riordan,et al.  Disease-associated Mutations in the Fourth Cytoplasmic Loop of Cystic Fibrosis Transmembrane Conductance Regulator Compromise Biosynthetic Processing and Chloride Channel Activity* , 1996, The Journal of Biological Chemistry.

[31]  A S Verkman,et al.  CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis. , 2006, Current pharmaceutical design.

[32]  J. Marshall,et al.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis , 1990, Cell.

[33]  Piotr Zielenkiewicz,et al.  Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain , 2013, EMBO molecular medicine.

[34]  P. Thomas,et al.  Building an understanding of cystic fibrosis on the foundation of ABC transporter structures , 2007, Journal of bioenergetics and biomembranes.

[35]  Pradeep Kota,et al.  Allosteric modulation balances thermodynamic stability and restores function of ΔF508 CFTR. , 2012, Journal of molecular biology.

[36]  Pradeep Kota,et al.  Regulatory insertion removal restores maturation, stability and function of DeltaF508 CFTR. , 2010, Journal of molecular biology.

[37]  A. M. George,et al.  Mechanism of the ABC transporter ATPase domains: catalytic models and the biochemical and biophysical record , 2013, Critical reviews in biochemistry and molecular biology.

[38]  M. Amaral,et al.  Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation. , 2008, Chemistry & biology.

[39]  G. Lukács,et al.  Mechanism-based corrector combination restores ΔF508-CFTR folding and function , 2013, Nature Chemical Biology.

[40]  Kai Du,et al.  The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR , 2005, Nature Structural &Molecular Biology.

[41]  Hong Yu Ren,et al.  VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1 , 2013, Molecular biology of the cell.

[42]  David Y. Thomas,et al.  Novel pharmacological strategies to treat cystic fibrosis. , 2013, Trends in pharmacological sciences.

[43]  W. Balch,et al.  Emergent properties of proteostasis in managing cystic fibrosis. , 2011, Cold Spring Harbor perspectives in biology.

[44]  John F Hunt,et al.  Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant. , 2010, Protein engineering, design & selection : PEDS.

[45]  John D. Venable,et al.  Hsp90 Cochaperone Aha1 Downregulation Rescues Misfolding of CFTR in Cystic Fibrosis , 2006, Cell.